Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05064358 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
- 20
- Study locations
NCT05064358 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 177 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05064358, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Conditions Studied
Interventions
- DRUG Belantamab mafodotin
Study Locations (20)
Other
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Capital Federal
- GSK Investigational Site - Ciudad Autonoma de Buenos Aire
- GSK Investigational Site - Pilar
- GSK Investigational Site - Rosario
- GSK Investigational Site - Joinville
- GSK Investigational Site - Porto Alegre
- GSK Investigational Site - Rio de Janeiro
- GSK Investigational Site - Salvador
- GSK Investigational Site - São Paulo
Tennessee
- GSK Investigational Site - Chattanooga
- GSK Investigational Site - Nashville
New South Wales
- GSK Investigational Site - Liverpool
- GSK Investigational Site - Newcastle
Florida
- GSK Investigational Site - West Palm Beach
Missouri
- GSK Investigational Site - Kansas City
New York
- GSK Investigational Site - New York
Texas
- GSK Investigational Site - Houston
South Australia
- GSK Investigational Site - Woodville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05064358
The ClinicalTrials.gov registry entry for NCT05064358 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Belantamab mafodotin is the first listed.
NCT05064358 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Tennessee, New South Wales.
Frequently Asked Questions
What is clinical trial NCT05064358 about?
NCT05064358 is a clinical study titled "Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma". This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
What is the current status of trial NCT05064358?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2022-03-03. Estimated completion is 2026-01-30.
What conditions does trial NCT05064358 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05064358?
The interventions under investigation include: Belantamab mafodotin (DRUG).
Who is sponsoring clinical trial NCT05064358?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05064358 being conducted?
This trial has 20 study locations across Florida, Missouri, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.